SGLT2 inhibitors reportedly lower daytime, nocturnal, and 24-h mean BP estimated by ambulatory BP monitoring (ABPM) in hypertensive patients with T2DM [14, 39, 48–52, 62]. Here, SLC5A2 is linked to type 2 diabetes mellitus.